PDS Biotechnology Corporation (PDSB)
NASDAQ:PDSB
Want to see PDSB full AI Analyst Report?
Earnings Data
Report Date
May 20, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.21Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical and IP progress — notably strong VERSATILE-002 survival data, promising early PDS01ADC signals, and FDA alignment on a protocol amendment that may accelerate regulatory timelines. Financials showed cost reductions and an improved net loss, but were tempered by a relatively small cash balance, higher net interest expense, and limited disclosure of the revised Phase III sample size and powering details. Overall, the positives around clinical momentum, patent protection into the 2040s, and decreased operating expenses outweigh the financial and execution uncertainties noted.Company Guidance
Strong Phase II Clinical Results (VERSATILE-002)
VERSATILE-002 showed a median overall survival (OS) of 39.3 months in patients with PD-L1 CPS/TPS ≥1 (95% CI lower bound 23.9 months, upper bound not yet estimable). Management described this as the first recurrent/metastatic head and neck population to report a median OS near 40 months, supporting the durability of PDS0101.
Phase III Protocol Amendment and FDA Alignment
Company obtained FDA no-objection after the standard 30-day review to amend VERSATILE-003 to make progression-free survival (PFS) an earlier interim primary endpoint (while retaining median OS for full approval). Management expects the PFS interim readout to be available in ~1.5 years and believes the amendment shortens trial duration and could enable accelerated approval.
Encouraging Early Data for PDS01ADC (NCI Study)
Early results from an NCI-led study of PDS01ADC + docetaxel in metastatic castration-resistant prostate cancer showed median PFS of 9.6 months, median PSA decline of 40%, and 6 of 16 patients (37.5%) achieving >50% PSA decline — suggesting potential activity in a heavily pretreated population.
Expanded Intellectual Property and Long-Term Market Protection
New patents granted in the United States and Japan for PDS0101, with combined U.S. patents plus anticipated biologics exclusivity expected to extend market protection into the 2040s; Japanese patent adds broad composition-of-matter claims.
Reduced Operating Costs and Improved Net Loss
Net loss for FY2025 narrowed to $34.5M (−$3.1M, −8.3%) from $37.6M in FY2024. Net loss per share improved to $0.74 vs $1.03 (−28.2%). Total operating expenses declined to $31.5M from $36.3M (−$4.8M, −13.2%).
Decreases in R&D and G&A Expenses
R&D expenses decreased to $19.0M from $22.6M (−$3.6M, −15.9%) driven by lower manufacturing (−$2.5M) and personnel costs (−$1.8M), partially offset by a $0.7M increase in clinical costs. G&A decreased to $12.5M from $13.8M (−$1.3M, −9.4%), primarily from lower personnel costs.
Site Retention and Improved Enrollment Environment
Management reported that no sites were lost during the trial pause, site response has been positive, and they expect brisk recruitment due to prior site experience and reduced competition for HPV16-positive enrollment.
PDSB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PDSB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 30, 2026 | $0.54 | $0.54 | -0.92% |
Nov 13, 2025 | $0.96 | $0.84 | -12.25% |
Aug 13, 2025 | $1.23 | $1.16 | -5.69% |
May 14, 2025 | $1.27 | $1.31 | +3.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does PDS Biotechnology Corporation (PDSB) report earnings?
PDS Biotechnology Corporation (PDSB) is schdueled to report earning on May 20, 2026, TBA (Confirmed).
What is PDS Biotechnology Corporation (PDSB) earnings time?
PDS Biotechnology Corporation (PDSB) earnings time is at May 20, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PDSB EPS forecast?
Currently, no data Available